Twenty four patients with multiple myeloma will be randomized to either AM group (administration of lenograstim at 8 am) or PM group (administration of lenograstim at 6 am ). Apheresis of hematopoietic stem cell will start at 10 am on D5 in AM group and at 8 am on D4 in PM group, respectively. Pharmacokinetic data of lenograstim will be correlated with pharmacodynamic data of CD34+ cell count, absolute neutrophil cell count and hematopoeitic progenitor cell count. In addition, the yield of stem cell collection between two arms will be analyzed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
24
Asan Medical Center, University of Ulsan College of Medicine
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
pharmacokinetic data of lenograstim
AUC0-24hr, Cmax, Cmin, Tmax, T1/2 of lenograstim
Time frame: on day 1 of apheresis
pharmacodynamic data: CD34+ cell count by flow cytometry
Time frame: on day 1 of apheresis
pharmacodynamic data: absolute neutrophil count
Time frame: on day 1 of apheresis
pharmacodynamic data: hematopoietic progenitor cells (HPC)
Time frame: on day 1 of apheresis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.